Table 1.
Top 15 antigens which are the targets of significantly higher IgG responses in DIV individuals 18 months after, compared to before PZQ treatment.
| Antigen (WBPS141 Accession) | Description | SI before treatment2 | SI after treatment3 | Fold change4 | P value6 | Selection method for array inclusion7 |
|---|---|---|---|---|---|---|
| MS3_07738 | MEG-8 family | 213.839 | 1995.197 | 9.330 | 0.004 | bioinformatic |
| MS3_02690 | synaptotagmin | 14.729 | 1916.206 | 130.096 | 0.039 | proteomic (T) |
| MS3_06745 | eukaryotic translation elongation factor 1 beta 2 | 304.375 | 1874.503 | 6.159 | 0.014 | proteomic (AES) |
| MS3_08159 | trematode eggshell synthesis domain containing protein | 44.755 | 1687.919 | 37.714 | 0.010 | bioinformatic |
| MS3_01775 | putative DNA-binding protein | 45.404 | 1520.667 | 33.492 | 0.013 | bioinformatic |
| MS3_03054 | chaperonin containing TCP1, subunit 5 (epsilon) | 247.255 | 1516.008 | 6.131 | 0.003 | proteomic (SEA) |
| MS3_09161 | thymidylate kinase | 221.841 | 1492.275 | 6.727 | 0.023 | proteomic (AES) |
| MS3_01938 | proliferating cell nuclear antigen | 358.357 | 1445.483 | 4.034 | 0.012 | bioinformatic |
| MS3_10116 | 60S ribosomal protein L23 | 238.344 | 1427.153 | 5.988 | 0.007 | bioinformatic |
| MS3_10687 | cathepsin B-like cysteine proteinase | 261.065 | 1398.814 | 5.358 | 0.042 | bioinformatic/EV homologue |
| MS3_03534 | UTP–glucose-1-phosphate uridylyltransferase | 110.807 | 1380.553 | 12.459 | 0.006 | proteomic (SEA) |
| MS3_04962 | interferon-related developmental regulator 1 | 389.531 | 1365.497 | 3.505 | 0.042 | bioinformatic |
| MS3_01693 | cystatin | 0.000 | 1365.483 | n/a5 | 0.007 | bioinformatic |
| MS3_08717 | NADH dehydrogenase 1 alpha subcomplex subunit 13 | 264.685 | 1363.492 | 5.151 | 0.014 | bioinformatic |
| MS3_02176 | microsomal glutathione S-transferase 3 | 94.896 | 1362.997 | 14.363 | 0.001 | proteomic (T) |
1WormBase ParaSite online database, version 14 https://parasite.wormbase.org/Schistosoma_haematobium_prjna78265/Info/Index/.
2mean signal intensity of DV cohort before PZQ treatment.
3mean signal intensity of DIV cohort 18 months after PZQ treatment.
4fold change in mean signal intensity of DIV cohort 18 months after PZQ treatment compared to DIV cohort before treatment.
5n/a = not assessed; fold change unable to be calculated due to mean signal intensity of CI cohort below the reactivity threshold.
6significance of difference in mean signal intensity of DIV cohort 18 months after PZQ treatment compared to DIV cohort before treatment.
7proteins for array inclusion selected from bioinformatic analysis of second-generation S. mansoni array (16) or analysis of S. haematobium proteomes (13, 14).
T, S. haematobium adult tegument, AES, S. haematobium adult excretory/secretory products, SEA, S. haematobium soluble egg antigen.